Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone LAI in Schizophrenia or Schizoaffective Disorders
NCT00526877Phase 4Completed
- Sponsor
- Johnson & Johnson
- Start
- Jul 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of risperidone in schizophrenia, schizoaffective disorder, sponsored by Johnson & Johnson. Started Jul 2007; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00526877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00526877.